| Nome |
# |
|
Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention, file e27ce42e-d0b6-2581-e053-d805fe0acbaa
|
10.252
|
|
Nonalcoholic fatty liver disease, file e27ce42b-7e84-2581-e053-d805fe0acbaa
|
10.199
|
|
Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis, file e27ce42e-44fc-2581-e053-d805fe0acbaa
|
4.928
|
|
Liver cancer: Connections with obesity, fatty liver, and cirrhosis, file e27ce42b-a3e6-2581-e053-d805fe0acbaa
|
2.239
|
|
From the metabolic syndrome to NAFLD or vice versa?, file e27ce426-bfdd-2581-e053-d805fe0acbaa
|
1.143
|
|
Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention, file e27ce42c-6d58-2581-e053-d805fe0acbaa
|
1.076
|
|
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial, file e27ce430-516f-2581-e053-d805fe0acbaa
|
1.067
|
|
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease, file e27ce430-4045-2581-e053-d805fe0acbaa
|
1.062
|
|
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions, file e27ce42b-87b6-2581-e053-d805fe0acbaa
|
1.016
|
|
Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults, file e27ce42b-a27e-2581-e053-d805fe0acbaa
|
954
|
|
Should we undertake surveillance for HCC in patients with NAFLD?, file e27ce42e-e9b3-2581-e053-d805fe0acbaa
|
872
|
|
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance, file e27ce42b-d6a6-2581-e053-d805fe0acbaa
|
827
|
|
[Non-alcoholic fatty liver disease (NAFLD)], file e27ce42b-9cf4-2581-e053-d805fe0acbaa
|
727
|
|
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis, file e27ce435-33d0-2581-e053-d805fe0acbaa
|
709
|
|
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease, file e27ce42b-ad14-2581-e053-d805fe0acbaa
|
650
|
|
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis, file e27ce430-486f-2581-e053-d805fe0acbaa
|
631
|
|
Management of non-alcoholic fatty liver disease, file e27ce432-d9fc-2581-e053-d805fe0acbaa
|
589
|
|
FibroGENE: A gene-based model for staging liver fibrosis, file e27ce42b-b4a9-2581-e053-d805fe0acbaa
|
497
|
|
Risk of non alcoholic steatohepatitis and fibrosis in patients with non alcoholic fatty liver disease and low visceral adiposity, file e27ce426-bfdc-2581-e053-d805fe0acbaa
|
491
|
|
Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine rich glycoprotein., file e27ce42d-1a8a-2581-e053-d805fe0acbaa
|
488
|
|
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening, file e27ce42b-a623-2581-e053-d805fe0acbaa
|
388
|
|
MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease, file e27ce42b-c5dd-2581-e053-d805fe0acbaa
|
359
|
|
Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents, file e27ce42e-a4c2-2581-e053-d805fe0acbaa
|
358
|
|
Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with Non-Alcoholic Fatty Liver: an external validation study, file e27ce42c-6c73-2581-e053-d805fe0acbaa
|
343
|
|
An extended fatty liver index to predict non-alcoholic fatty liver disease., file e27ce42b-73d6-2581-e053-d805fe0acbaa
|
339
|
|
Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists, file e27ce42b-9c5d-2581-e053-d805fe0acbaa
|
339
|
|
Preparing for the NASH Epidemic: A Call to Action, file e27ce435-548a-2581-e053-d805fe0acbaa
|
335
|
|
Circulating Zonulin is Related to Hepatic Necroinflammation in Patients with Non Alcoholic Fatty Liver Disease, file e27ce42f-5aa2-2581-e053-d805fe0acbaa
|
331
|
|
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study, file e27ce42b-9b60-2581-e053-d805fe0acbaa
|
326
|
|
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation, file e27ce430-22d0-2581-e053-d805fe0acbaa
|
312
|
|
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease., file e27ce426-c3e7-2581-e053-d805fe0acbaa
|
307
|
|
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates, file e27ce42d-dfb0-2581-e053-d805fe0acbaa
|
301
|
|
NASH in lean individuals, file e27ce42e-2626-2581-e053-d805fe0acbaa
|
291
|
|
Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with Nonalcoholic Fatty Liver Disease, file e27ce430-4b01-2581-e053-d805fe0acbaa
|
278
|
|
Alteration in lipid metabolism after an oral fat load in subjects with NAFLD., file e27ce426-fc71-2581-e053-d805fe0acbaa
|
267
|
|
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis, file e27ce42b-6c19-2581-e053-d805fe0acbaa
|
263
|
|
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes, file e27ce42b-9255-2581-e053-d805fe0acbaa
|
263
|
|
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C, file e27ce428-a713-2581-e053-d805fe0acbaa
|
259
|
|
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation, file e27ce430-4bb9-2581-e053-d805fe0acbaa
|
258
|
|
Undernutrition, risk of malnutrition and obesity in gastroenterological patients: A multicenter study, file e27ce42b-a0e5-2581-e053-d805fe0acbaa
|
250
|
|
Non-invasive score system for fibrosis in chronic hepatitis: Proposal for a model based on biochemical, FibroScan and ultrasound data, file e27ce42b-887d-2581-e053-d805fe0acbaa
|
238
|
|
Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease, file e27ce42a-5574-2581-e053-d805fe0acbaa
|
236
|
|
Altered metabolic profile and adipocyte insulin resistance mark severe liver fibrosis in patients with chronic liver disease, file e27ce42f-3522-2581-e053-d805fe0acbaa
|
233
|
|
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis, file e27ce42b-8a1c-2581-e053-d805fe0acbaa
|
226
|
|
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH), file e27ce42c-731f-2581-e053-d805fe0acbaa
|
224
|
|
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study, file e27ce42e-18f4-2581-e053-d805fe0acbaa
|
218
|
|
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load, file e27ce428-a78c-2581-e053-d805fe0acbaa
|
212
|
|
Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?, file e27ce42a-2ebd-2581-e053-d805fe0acbaa
|
200
|
|
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease, file e27ce42b-a8c4-2581-e053-d805fe0acbaa
|
200
|
|
Should we undertake surveillance for HCC in patients with NAFLD?, file e27ce42c-4cdc-2581-e053-d805fe0acbaa
|
198
|
|
Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice, file e27ce426-f106-2581-e053-d805fe0acbaa
|
192
|
|
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic patients with chronic hepatitis C., file e27ce426-d4ef-2581-e053-d805fe0acbaa
|
189
|
|
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease., file e27ce426-fb66-2581-e053-d805fe0acbaa
|
189
|
|
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?, file e27ce428-bb67-2581-e053-d805fe0acbaa
|
183
|
|
LIVER DAMAGE CAN BE ASSOCIATED WITH DEREGULATION OF THE DE NOVO LIPOGENESIS PATHWAY IN SUBJECTS WITH NON ALCOHOLIC FATTY LIVER DISEASE, file e27ce428-ae68-2581-e053-d805fe0acbaa
|
181
|
|
Increased liver expression of inflammatory mediators is associated with hepatic insulin resistance in lean, non-diabetic CHC patients., file e27ce426-d4ee-2581-e053-d805fe0acbaa
|
180
|
|
Metabolic significance of hepatic steatosis in non alcoholic fatty liver disease and HCV chronic hepatitis, file e27ce426-d485-2581-e053-d805fe0acbaa
|
179
|
|
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference, file e27ce42b-90d1-2581-e053-d805fe0acbaa
|
179
|
|
A "systems medicine" approach to the study of non-alcoholic fatty liver disease., file e27ce42a-9dbb-2581-e053-d805fe0acbaa
|
174
|
|
Increased LDL-cholesterol susceptibility to oxidation contributes to oxidative damage in non alcoholic steatohepadtis (NASH)., file e27ce426-d483-2581-e053-d805fe0acbaa
|
173
|
|
HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients, file e27ce42b-8b34-2581-e053-d805fe0acbaa
|
173
|
|
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry, file e27ce435-7706-2581-e053-d805fe0acbaa
|
173
|
|
AISF position paper on liver disease and pregnancy., file e27ce429-082c-2581-e053-d805fe0acbaa
|
171
|
|
Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids, file e27ce42b-0734-2581-e053-d805fe0acbaa
|
171
|
|
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients., file e27ce426-e4b1-2581-e053-d805fe0acbaa
|
169
|
|
Pathophysiology of non alcoholic fatty liver disease, file e27ce42b-9c43-2581-e053-d805fe0acbaa
|
164
|
|
Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis, file e27ce42b-4293-2581-e053-d805fe0acbaa
|
163
|
|
Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients., file e27ce426-e6df-2581-e053-d805fe0acbaa
|
161
|
|
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease, file e27ce428-afc8-2581-e053-d805fe0acbaa
|
161
|
|
Obesity: Childhood obesity: Time bomb for future burden of chronic liver disease, file e27ce42b-d1d1-2581-e053-d805fe0acbaa
|
159
|
|
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals, file e27ce42c-01de-2581-e053-d805fe0acbaa
|
158
|
|
Fatty liver disease: putting the spotlight on a silent menace for young adults, file e27ce42f-0f47-2581-e053-d805fe0acbaa
|
148
|
|
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease, file e27ce426-fa8b-2581-e053-d805fe0acbaa
|
145
|
|
Association Between Gut Permeability and Insulin Resistance: Any Role for Zonulin in Patients with Non-Alcoholic Fatty Liver Disease?, file e27ce431-38ec-2581-e053-d805fe0acbaa
|
145
|
|
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease, file e27ce42a-1697-2581-e053-d805fe0acbaa
|
141
|
|
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease, file e27ce42c-01df-2581-e053-d805fe0acbaa
|
141
|
|
Advancing the global public health agenda for NAFLD: a consensus statement, file e27ce435-7571-2581-e053-d805fe0acbaa
|
137
|
|
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight, file d1ec906c-f6e5-4b27-a579-b567fed092ff
|
136
|
|
Non-alcoholic fatty liver disease and extra-hepatic cancers, file e27ce42b-757f-2581-e053-d805fe0acbaa
|
135
|
|
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR, file e27ce42e-2473-2581-e053-d805fe0acbaa
|
135
|
|
How to diagnose NAFLD in 2016, file e27ce42a-34d2-2581-e053-d805fe0acbaa
|
134
|
|
Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States, file e27ce42e-5571-2581-e053-d805fe0acbaa
|
134
|
|
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis, file e27ce435-560f-2581-e053-d805fe0acbaa
|
132
|
|
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis., file e27ce429-0914-2581-e053-d805fe0acbaa
|
131
|
|
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C, file e27ce42b-8384-2581-e053-d805fe0acbaa
|
128
|
|
The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study, file e27ce430-db6b-2581-e053-d805fe0acbaa
|
127
|
|
Basic and clinical aspects of resistin, file e27ce42e-afb7-2581-e053-d805fe0acbaa
|
121
|
|
A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD, file e27ce42e-2619-2581-e053-d805fe0acbaa
|
120
|
|
Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease, file e27ce42b-967b-2581-e053-d805fe0acbaa
|
118
|
|
High-throughput RNA sequencing unravels pathways associated with the progression of non-alcoholic liver disease, file e27ce42b-6faa-2581-e053-d805fe0acbaa
|
113
|
|
Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease, file e27ce42d-c7d7-2581-e053-d805fe0acbaa
|
111
|
|
Reply, file e27ce42e-5cd9-2581-e053-d805fe0acbaa
|
110
|
|
Metabolic Syndrome and Severity of Fibrosis in Nonalcoholic Fatty Liver Disease: An Age-Dependent Risk Profiling Study, file e27ce42a-3756-2581-e053-d805fe0acbaa
|
109
|
|
Hypoxia-inducible factor 2alpha drives the progression of experimental non-alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein, file e27ce42b-b995-2581-e053-d805fe0acbaa
|
108
|
|
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis, file e27ce42c-b0fb-2581-e053-d805fe0acbaa
|
108
|
|
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura, file e27ce42a-f451-2581-e053-d805fe0acbaa
|
107
|
|
The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality, file e27ce42e-ed6b-2581-e053-d805fe0acbaa
|
107
|
|
Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts., file e27ce42f-193f-2581-e053-d805fe0acbaa
|
107
|
|
Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction, file e27ce42b-89c6-2581-e053-d805fe0acbaa
|
105
|
|
A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification, file e27ce430-144b-2581-e053-d805fe0acbaa
|
104
|
| Totale |
56.008 |